CMS unveils the Medicare GLP-1 Bridge at $50 a month

The Centers for Medicare & Medicaid Services announced on May 6, 2026 that eligible Medicare Part D beneficiaries will be able to get certain GLP-1 medications for $50 per month starting July 1, 2026, through December 31, 2027 ^[1]. The program, called the Medicare GLP-1 Bridge, is a time-limited demonstration and marks the first time Medicare has offered a pathway to coverage for drugs prescribed for weight management ^[1][3].

Medicare has long been barred from covering weight-loss treatments ^[3]. CMS is getting around that using demonstration authority under Section 402(a)(1)(A) of the Social Security Amendments of 1967, as made applicable to Part D by section 1860D-42(b) of the Social Security Act, which lets the Secretary test changes in payment methods ^[2].

What is covered and who qualifies

The pilot covers GLP-1 medications approved for weight loss: the pill and injectable forms of Wegovy (semaglutide), the KwikPen formulation of Zepbound (tirzepatide), and the Foundayo pill (orforglipron) ^[3].

To participate, a person must be enrolled in a Medicare Part D plan. Beyond that, eligibility is based mainly on body weight and health status: people qualify with a body mass index of 27 or higher plus a condition such as heart disease or prediabetes, among others, and people with a BMI of 35 or higher automatically qualify ^[3]. About 40% of American adults are clinically obese with a BMI of 30 or higher, according to the CDC ^[3].

The mechanics are unusual. The Bridge operates outside the Part D benefit's coverage and payment flow, so Part D sponsors carry no risk for these drugs and do not have to opt in for their members to get access ^[2]. In 2026, CMS is using a single central processor to handle prior authorization, claims and payment to pharmacies ^[2]. Prescribers send the prescription and prior authorization request to that central system, run by CMS contractor Humana, and doctors do not need to be enrolled as Medicare providers to do so ^[3]. After approval, the patient pays the flat $50 at the pharmacy ^[3].

Why it matters for patients

The $50 copay is a fixed amount that does not rise as the dose goes up ^[3]. For comparison, NPR reports that cash prices, even with discounts, typically run $149 to $699 a month; on the government's TrumpRx site, Wegovy injectables range from $199 for a lower dose in the first two months to $399 at higher doses, the Zepbound KwikPen runs up to $699 a month, the daily Wegovy pill up to $299, and Foundayo up to $349 ^[3]. About half of GLP-1 users told KFF the drugs were difficult to afford, and a quarter said "very difficult" ^[3].

The trade-offs are specific. Because the drugs sit outside the Part D benefit, the Part D deductible does not apply, none of the $50 counts toward true out-of-pocket (TrOOP) costs or the $2,100 annual cap on prescription drug spending, and there is no low-income subsidy ^[2][3]. Juliette Cubanski of KFF noted that for someone accustomed to a $5 or $10 copay, "$50 a month sounds like a great deal compared to paying the discounted prices through TrumpRx... but it's a lot of money for somebody who's living on a $750-a-month Social Security check" ^[3].

The $50 price is only for weight loss. People already taking these drugs for Type 2 diabetes, cardiovascular risk reduction or sleep apnea keep getting them through their regular Part D plan at their plan's price, which may be higher — so the same drug can cost different amounts depending on why it was prescribed ^[3]. People already on a GLP-1 for weight loss may qualify if their prescriber attests they met the clinical criteria when they first started the drug ^[3].

What happens next

The Bridge was originally planned as a six-month program leading into a longer-term model, BALANCE, that would shift drug costs to insurers ^[3]. Not enough insurers signed on by the April deadline, so CMS extended the Bridge to 18 months, ending December 2027, partly to collect utilization data to share with Part D plans ahead of possible BALANCE implementation ^[2][3].

What happens after December 2027 is not yet settled. CMS has not publicly released cost projections; Cubanski estimated the Bridge is "likely to be billions of dollars a year in additional spending for Medicare" ^[3]. Beneficiaries can check eligibility at Medicare.gov/glp1bridge or call 1-800-MEDICARE ^[2].